NS101 IV infusion for Neurodegenerative Disease

"The cut-off age for this trial is 55 years old, and those aged 18 to 55 are eligible. Moreover, there are separate clinical trials available to minors (under the age of 18) as well as seniors over 65."

"The records on clinicaltrials.gov show that this trial is not currently recruiting patients, even though it was initially posted on November 4th 2021 and last updated on August 23rd 2022. Nevertheless, 45 other medical trials are actively searching for participants at the moment."

"For this medical trial, 64 patients with neurodegenerative diseases will be recruited and must satisfy the following criteria: male candidates aged between 18-55 years old; body mass index ranging from 18.5 to 30 kg/m2 (50 kg minimum for males); no smoking or nicotine consumption in the past 6 months; no significant illness within 4 weeks prior to dosing; absence of clinically relevant neurological, endocrine, cardiovascular, respiratory hematological immunological psychiatric gastrointestinal renal hepatic and metabolic disease; score 0 on Sheehan Suicidality Tracking Scale at screening."

"With limited evidence of efficacy and safety, NS101 IV infusion scored a 1 on our team's scale. As this is only a Phase 1 trial, more clinical data must be collected before its safety can be fully established."